Department of Radiation Oncology, CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Int J Gynecol Cancer. 2011 Aug;21(6):1117-23. doi: 10.1097/IGC.0b013e31821dc8b5.
A ratio of 3 months of posttherapy to pretherapy 2-[F]fluoro-2-deoxy-d-glucose positron emission tomography with computed tomography (F-FDG PET/CT) standard uptake values (SUVs) predicts progression-free survival after chemoradiation in patients with stages IB2 to IVA cervical cancer.
This retrospective review included 51 patients who received treatments of daily pelvic radiation and once-weekly cisplatin chemotherapy followed by brachytherapy. Posttherapy confirmatory surgical or cytologic pathology was done a median of 7 days after 3-month F-FDG PET/CT.
All 51 patients receiving chemoradiation achieved at least a partial metabolic response (ie, >25% decrease in F-FDG PET/CT SUV) in the expected region of the cervix. A ratio of less than 0.33 for posttherapy to pretherapy F-FDG PET/CT SUVs of the expected area of the cervix was associated with a 35% improvement in 6-month progression-free survival.
In patients with cervical cancer, the 3-month posttherapy F-FDG PET/CT value is an indicator of therapeutic response to chemoradiation and needs further validation in clinical trials.
在接受同步放化疗的 IB2 至 IVA 期宫颈癌患者中，治疗后 3 个月与治疗前的 2-[F]氟-2-脱氧-d-葡萄糖正电子发射断层扫描与计算机断层扫描（F-FDG PET/CT）标准摄取值（SUV）比值可预测无进展生存期。
本回顾性研究纳入了 51 例接受每日盆腔放疗和每周一次顺铂化疗后行近距离放疗的患者。治疗后 3 个月行 F-FDG PET/CT 检查，中位时间为 7 天后进行确认性手术或细胞学病理检查。
所有接受放化疗的 51 例患者均在预期宫颈区域达到至少部分代谢反应（即 F-FDG PET/CT SUV 降低>25%）。预期宫颈区域治疗后与治疗前 F-FDG PET/CT SUV 比值小于 0.33 与 6 个月无进展生存率提高 35%相关。
在宫颈癌患者中，治疗后 3 个月的 F-FDG PET/CT 值是对放化疗治疗反应的指标，需要在临床试验中进一步验证。
